SEZ6L2 and glioblastoma: Specifically, overexpression of SEZ6L2 has been linked to an unfavorable outcome in glioblastoma [12], colorectal cancer [28, 29], cholangiocarcinoma [13], lung adenocarcinoma [15], non-small cell lung cancer [10], thyroid cancer [30], hepatocellular carcinoma [31], and breast cancer [11].